

Andrew Tutt

Andrew Tutt qualified in Medicine in 1990. After postgraduate training in General Medicine, he trained in Clinical Oncology at the Royal Marsden Hospital, before gaining a Doctoral Research Training Fellowship from the Medical Research Council, to work in Professor Alan Ashworth's laboratory at The Institute of Cancer Research.

Here he worked on the then unknown DNA repair functions of the *BRCA2* breast cancer predisposition gene, and described the role of *BRCA2* in homologous recombination (HR). He was awarded his PhD in 2002. In his postdoctoral work as a Clinician Scientist, he identified the synthetic lethality between PARP inhibitors and *BRCA1/2* mutations with Dr Chris Lord and Professor Alan Ashworth.

He went on to design the single agent PARP inhibitor Proof of Concept Phase I trials and associated DNA repair biomarker studies with the ICR and Royal Marsden Drug Development Unit, and has since lead international Phase II and III trials, examining the role of HR directed therapies including PARP inhibitors and platinum for *BRCA1 / BRCA2* deficiency associated malignancy including; the TNT trial, which changed clinical practice for patients with *BRCA1/1* mutated breast cancer.

He cares for women with breast cancer as a Consultant Oncologist, and as a member of the multidisciplinary Breast Units at Guy's and St Thomas' and Royal Marsden NHS Foundation Trusts. Andrew is also a member of the St Gallen Early Breast Cancer International Consensus Panel and the Oxford Early Breast Cancer Trialists Cooperative Group (EBCTCG).

He is Professor of Breast Oncology and Director of the Breast Cancer Now Toby Robins Research Centre, at the Institute of Cancer Research (ICR) and King's College London, and Head of the Division of Breast Cancer Research at the ICR.

Andrew leads a clinical trial programme focusing on TNBC and cancers associated with functional deficiencies in *BRCA1* and *BRCA2*. He also leads translational laboratories at both the ICR and KCL, studying *BRCA1* and *BRCA2* associated and Triple Negative forms of breast cancer (TNBC). Their recent work included new TNBC targets, PIM1 and KIFCI, published in Nature Medicine and Nature Communications.

Andrew's group have also published papers from these programmes in the journals Nature, The New England Journal of Medicine, The Lancet, Nature Medicine, Journal of Clinical Oncology, Cancer Research, Science Translational Medicine and Cancer Discovery. He is Chief Investigator for the multicentre UKCRN "Triple Negative Trial", recently reported in Nature Medicine, and is Global Study Chair of the 'OlympiA' study – an adjuvant PARP inhibitor trial in patients with germline *BRCA1/2* mutations and breast cancer.

He has been a visiting Professor at British Columbia Cancer Agency, and Jean Lubrano visiting Scholar at Harvard Medical School. In 2015 he received the Addarii Award for his work in the field of *BRCA1* and *BRCA2* associated breast and ovarian cancer research. Andrew was recently elected to the Fellowship of the Academy of Medical Sciences.